From start on, a major goal of INNODIA was to undertake clinical intervention studies and to pave the way for the development of novel treatments to prevent and cure Type 1 Diabetes.
INNODIA is now performing mechanistic-based clinical studies, using a Master-Protocol established within INNODIA.
Well-designed clinical trials give participants an opportunity to play an active role in their own #healthcare, help others to the advancement of medical knowledge, gain access to new research treatments and obtain expert medical care at leading healthcare facilities during the trial. https://lnkd.in/gr4zCHQ
Imcyse is a clinical stage biopharmaceutical company pioneering the development of a new class of active specific immunotherapies for the treatment of severe chronic autoimmune diseases. The company’s unique technology platform allows it to locally target immune cells involved in the destruction of the diseased organ. This platform is based on the administration of Imotopes™, which are specifically modified peptides, allowing for the generation of cytolytic CD4 T-cells, that specifically eliminate antigen-presenting cells and autoantigen specific lymphocytes. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no current therapeutic alternative and to potentially cure patients without impairing immune defense. The company has established proof of concept in several indications and has completed its first clinical trial in type 1 diabetes with promising results. Beyond type 1 diabetes, Imcyse is developing a pipeline of Imotopes™ for the treatment of several autoimmune diseases. Founded as a spin-off of the Catholic University of Leuven in 2011, Imcyse subsequently relocated to Liège, Belgium.
Chief Executive Officer
FOR MEDIA INQUIRES:
MC Services AG
Anne Hennecke / Brittney Sojeva
Tel.: +49 (0) 211-529-252-14